Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …

Objective: Determine whether a novel psychosocial treatment for positive affect improves
clinical status and reward sensitivity more than a form of cognitive behavioral therapy that …

Background Anhedonia is considered a suicide risk factor in patients with major affective
disorders. Here, we wanted to quantify the association between anhedonia and current …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Background Persons with suicidality including suicidal ideation (SI), suicide plans (SP)
and/or suicide attempts (SA) are at higher risk for future suicide than those without …

Background: More than 2% of the general population experience suicidal ideas each year
and a large number of them will attempt suicide. Evidence-based therapeutic options to …

In rodent models of depression,(R)-ketamine has greater potency and longer-lasting
antidepressant effects than (S)-ketamine; however, the precise molecular mechanisms …

For decades, symptoms of depression have been treated primarily with medications that
directly target the monoaminergic brain systems, which typically take weeks to exert …